Liquid biopsy for early tumor relapse detection

• Autores: Pau Rodriguez Sodupe
• Directores de la Tesis: Jairo Rodríguez Lumbiarres (dir. tes.), Luis Pérez Jurado (codir. tes.)
• Lectura: En la Universitat Pompeu Fabra ( España ) en 2022
• Idioma: inglés
• Tribunal Calificador de la Tesis: Soledad Gallego Melcón (presid.), Robert Castelo Valdueza (secret.), Eduard Serra Arenas (voc.)
• Programa de doctorado: Programa de Doctorado en Biomedicina por la Universidad Pompeu Fabra
• Texto completo no disponible (Saber más ...)
• Resumen

  • The profiling of circulating-tumor DNA (ctDNA) in blood plasma, often known as liquid biopsy, has recently been of great interest in cancer research. This minimally-invasive strategy relies on the fact that ctDNA represents, at least partially, the real-time state of the tumor genome and holds great potential for early cancer detection and patient care. However, the fraction of ctDNA in total cell-free DNA (cfDNA) is often very low and requires ultra-sensitive and specific methods for its detection.

    This thesis focuses on the development and implementation of ultra-sensitive Next Generation Sequencing (NGS) methods that enable the identification of rare variants in plasma in a specific way. In summary, this work presents a comprehensive and cost-effective strategy for monitoring tumor mutations in the plasma of pediatric patients in a personalized manner. Our strategy aims to provide a tool to anticipate the detection and treatment of tumor relapses.